- Home
- MGNI vs KNSA Comparison
MGNI vs KNSA Comparison
Compare MGNI & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNI
- KNSA
- Stock Information
- Founded
- MGNI 2007
- KNSA 2015
- Country
- MGNI United States
- KNSA United Kingdom
- Employees
- MGNI N/A
- KNSA N/A
- Industry
- MGNI Computer Software: Programming Data Processing
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- MGNI Technology
- KNSA Health Care
- Exchange
- MGNI Nasdaq
- KNSA Nasdaq
- Market Cap
- MGNI 1.4B
- KNSA 1.5B
- IPO Year
- MGNI N/A
- KNSA 2018
- Fundamental
- Price
- MGNI $11.13
- KNSA $20.21
- Analyst Decision
- MGNI Strong Buy
- KNSA Strong Buy
- Analyst Count
- MGNI 14
- KNSA 6
- Target Price
- MGNI $18.82
- KNSA $37.17
- AVG Volume (30 Days)
- MGNI 3.0M
- KNSA 638.0K
- Earning Date
- MGNI 05-07-2025
- KNSA 04-29-2025
- Dividend Yield
- MGNI N/A
- KNSA N/A
- EPS Growth
- MGNI N/A
- KNSA N/A
- EPS
- MGNI 0.16
- KNSA N/A
- Revenue
- MGNI $668,170,000.00
- KNSA $423,239,000.00
- Revenue This Year
- MGNI $2.04
- KNSA $37.21
- Revenue Next Year
- MGNI $10.89
- KNSA $2.58
- P/E Ratio
- MGNI $69.56
- KNSA N/A
- Revenue Growth
- MGNI 7.82
- KNSA 56.60
- 52 Week Low
- MGNI $8.22
- KNSA $16.56
- 52 Week High
- MGNI $21.29
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- MGNI 47.29
- KNSA 44.56
- Support Level
- MGNI $9.64
- KNSA $18.26
- Resistance Level
- MGNI $10.26
- KNSA $21.24
- Average True Range (ATR)
- MGNI 1.01
- KNSA 1.12
- MACD
- MGNI 0.20
- KNSA -0.12
- Stochastic Oscillator
- MGNI 82.91
- KNSA 44.43
About MGNI Magnite Inc.
Magnite Inc is one of the supply-side platform providers, or SSP, in online advertising. The firm generate its revenue from the programmatic sale of CTV ad inventory, from mobile online sites and apps, and the remaining from websites accessed via computer.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.